Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG

Michele Tameris, Helen McShane, J Bruce McClain, Bernard Landry, Stephen Lockhart, Angelique K K Luabeya, Hennie Geldenhuys, Jacqui Shea, Gregory Hussey, Linda van der Merwe, Marwou de Kock, Thomas Scriba, Robert Walker, Willem Hanekom, Mark Hatherill, Hassan Mahomed, Michele Tameris, Helen McShane, J Bruce McClain, Bernard Landry, Stephen Lockhart, Angelique K K Luabeya, Hennie Geldenhuys, Jacqui Shea, Gregory Hussey, Linda van der Merwe, Marwou de Kock, Thomas Scriba, Robert Walker, Willem Hanekom, Mark Hatherill, Hassan Mahomed

Abstract

Background: New tuberculosis (TB) vaccines are being developed to combat the global epidemic. A phase IIb trial of a candidate vaccine, MVA85A, was conducted in a high burden setting in South Africa to evaluate proof-of-concept efficacy for prevention of TB in infants.

Objective: To describe the study design and implementation lessons from an infant TB vaccine efficacy trial.

Methods: This was a randomised, controlled, double-blind clinical trial comparing the safety and efficacy of MVA85A to Candin control administered to 4-6-month-old, BCG-vaccinated, HIV-negative infants at a rural site in South Africa. Infants were followed up for 15-39 months for incident TB disease based on pre-specified endpoints.

Results: 2797 infants were enrolled over 22 months. Factors adversely affecting recruitment and the solutions that were implemented are discussed. Slow case accrual led to six months extension of trial follow up.

Conclusion: The clinical, regulatory and research environment for modern efficacy trials of new TB vaccines are substantially different to that when BCG vaccine was first evaluated in infants. Future infant TB vaccine trials will need to allocate sufficient resources and optimise operational efficiency. A stringent TB case definition is necessary to maximize specificity, and TB case accrual must be monitored closely.

Copyright © 2013 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Main reasons for screening failure.

References

    1. World Health Organisation . 2006. Guidance for national tuberculosis programmes on the management of tuberculosis in children.
    1. Trunz B.B., Fine P., Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–1180.
    1. Department of Health . Department of Health and Medical Research Council; Pretoria, South Africa: 1999. South Africa demographic and health survey 1998.
    1. World Health Organisation . 2011. Global tuberculosis control.
    1. Rodrigues L.C., Diwan V.K., Wheeler J.G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993;22:1154–1158.
    1. Fine P.E.M., Carneiro I.A.M., Milstein J.B., Clements C.J. WHO; Geneva: 1999. Issues relating to the use of BCG in immunization programs.
    1. Stop TB Working Group on TB vaccines . 2011. TB vaccine pipeline. [accessed 14.08.12]
    1. McShane H., Behboudi S., Goonetilleke N., Brookes R., Hill A.V. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun. 2002;70:1623–1626.
    1. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med. 2012;185:769–778.
    1. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis. 2011;203:1832–1843.
    1. Scriba T.J., Tameris M., Mansoor N., Smit E., van der Merwe L. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010;40:279–290.
    1. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008;198:544–552.
    1. Sander C.R., Pathan A.A., Beveridge N.E., Poulton I., Minassian A. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med. 2009;179:724–733.
    1. Brookes R.H., Hill P.C., Owiafe P.K., Ibanga H.B., Jeffries D.J. Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One. 2008;3:e2921.
    1. Beveridge N.E., Price D.A., Casazza J.P., Pathan A.A., Sander C.R. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol. 2007;37:3089–3100.
    1. Minassian A.M., Rowland R., Beveridge N.E., Poulton I.D., Satti I. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open. 2011;1:e000223.
    1. Pathan A.A., Minassian A.M., Sander C.R., Rowland R., Porter D.W. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine. 2012;30:5616–5624.
    1. Odutola A.A., Owolabi O.A., Owiafe P.K., McShane H., Ota M.O. A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. Vaccine. 2012;30:5591–5594.
    1. Ota M.O., Odutola A.A., Owiafe P.K., Donkor S., Owolabi O.A. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med. 2011;3:88ra56.
    1. Aronson J.D., Palmer C.E. Experience with BCB vaccine in the control of tuberculosis among North American Indians. Public Health Rep. 1946;61:802–820.
    1. Rosenthal S.R., Loewinsohne, Graham M.L., Liveright D., Thorne G. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics. 1961;28:622–641.
    1. Hatherill M. Prospects for elimination of childhood tuberculosis: the role of new vaccines. Arch Dis Child. 2011;96:851–856.
    1. Mulenga H., Moyo S., Workman L., Hawkridge T., Verver S. Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials. Vaccine. 2011;29:4316–4321.
    1. Hatherill M., Verver S., Mahomed H., Taskforce on Clinical Research Issues STBPWGoTBV Consensus statement on diagnostic end points for infant tuberculosis vaccine trials. Clin Infect Dis. 2012;54:493–501.
    1. Marais B.J., Gie R.P., Schaaf H.S., Starke J.R., Hesseling A.C. A proposed radiological classification of childhood intra-thoracic tuberculosis. Pediatr Radiol. 2004;34:886–894.
    1. Hawkridge A., Hatherill M., Little F., Goetz M.A., Barker L. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ. 2008;337:a2052.
    1. English R. Department of Health; 2010. Boland/Overberg region health status report 2007/2008.
    1. Moyo S., Verver S., Hawkridge A., Geiter L., Hatherill M. Tuberculosis case finding for vaccine trials in young children in high-incidence settings: a randomised trial. Int J Tuberc Lung Dis. 2012;16:185–191.
    1. Geldenhuys H., Waggie Z., Jacks M., Geldenhuys M., Traut L. Vaccine trials in the developing world: operational lessons learnt from a phase IV poliomyelitis vaccine trial in South Africa. Vaccine. 2012
    1. Harrison D., Stevens B., Bueno M., Yamada J., Adams-Webber T. Efficacy of sweet solutions for analgesia in infants between 1 and 12 months of age: a systematic review. Arch Dis Child. 2010;95:406–413.
    1. Willock J., Richardson J., Brazier A., Powell C., Mitchell E. Peripheral venepuncture in infants and children. Nurs Stand. 2004;18:43–50. quiz 52, 55–46.
    1. Hatherill M., Hanslo M., Hawkridge T., Little F., Workman L. Structured approaches for the screening and diagnosis of childhood tuberculosis in a high prevalence region of South Africa. Bull World Health Organ. 2010;88:312–320.
    1. Mahomed H., Fourie P.B. Clinical trials of TB vaccines: harmonization and cooperation. Tuberculosis (Edinb) 2012;92(Suppl. 1):S21–S24.
    1. Graham S.M., Ahmed T., Amanullah F., Browning R., Cardenas V. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis. 2012;205(Suppl. 2):S199–S208.
    1. Department of Health . Department of Health; Pretoria, South Africa: 2006. Guidelines for good practice in the conduct of clinical trials with Human participants in South Africa.
    1. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 1996. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1) Step 4 Version.
    1. Lubega I.R., Fowler M.G., Musoke P.M., Elbireer A., Bagenda D. Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy Malawian and Ugandan infants. J Acquir Immune Defic Syndr. 2011;55:58–64.
    1. Buchanan A.M., Muro F.J., Gratz J., Crump J.A., Musyoka A.M. Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region. Trop Med Int Health. 2010
    1. Lugada E.S., Mermin J., Kaharuza F., Ulvestad E., Were W. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004;11:29–34.
    1. Quinto L., Aponte J.J., Sacarlal J., Espasa M., Aide P. Haematological and biochemical indices in young African children: in search of reference intervals. Trop Med Int Health. 2006;11:1741–1748.
    1. Troy S.B., Rowhani-Rahbar A., Dyner L., Musingwini G., Shetty A.K. Hematologic and immunologic parameters in Zimbabwean infants: a case for using local reference intervals to monitor toxicities in clinical trials. J Trop Pediatr. 2012;58:59–62.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit